MaKe | MaHui Member Bota Bio Enhe Biotechnology Celebrates Fifth Anniversary, Bringing Biotechnology into Daily Life

This article is republished from VBData

On a global scale, synthetic biology is reshaping how people understand biotechnology, biomanufacturing, and everyday applications — and gradually weaving itself into daily life.

Whether it's natural flavorings, nutritional supplements, bio-based raw materials, or high-performance skincare actives, the boundaries of synthetic biology's everyday applications keep expanding. How to push laboratory innovations toward broader commercialization — into supermarkets, restaurants, and households — has become an inexhaustible driving force for synthetic biology companies to pursue technological maturity, scale-up, cost reduction, and accelerated commercialization.

On September 26, Bota Bio (Enhe Biotechnology) hosted the forum Evolution and Breakthrough: Biotechnology Enters Everyday Life — Frontier Exploration in Biology in Hangzhou. The event brought together experts and scholars from government, industry, academia, and research, along with partners, investors, and industry representatives, to share Bota Bio's development journey and outstanding achievements over the past five years, discuss opportunities for the next five, and explore the latest advances in synthetic biology and its practical applications across multiple industries.

We cannot ignore one trend: in the future, synthetic biology will drive industrial upgrading in every dimension, and biomanufactured products will enter every application scenario of daily life. Bota Bio is racing toward this goal. On its fifth anniversary, the company has achieved milestone results and is contributing to the empowerment of industrial development through synthetic biology technology.

Building the Bota Freeway® Biofoundry Platform to Achieve Industrial Scale-Up and Commercialization Breakthroughs

For synthetic biology companies, technology platforms are as important as products themselves. From its founding to its current commercialization phase, Bota Bio chose to leverage its team strengths by first building a cutting-edge technology platform, then going deep into industry, selecting verticals based on market demand, and executing industrialization.

Within five years, Bota Bio developed its high-throughput automated strain and process development platform, Bota Freeway® Biofoundry, covering the full chain from laboratory R&D to industrial-scale production in synthetic biology. The platform's advantages lie in its intelligent design capabilities and systematic, high-throughput engineering capabilities — particularly its development capabilities for non-model industrial strains, which distinguish Bota Bio's R&D platform from others.

Facing the bottleneck challenge in biomanufacturing — industrial scale-up and commercialization — Bota Bio uses massive data accumulation and scientific expertise to achieve scale-up through a more comprehensive, multidisciplinary approach, driving the mass production of research outcomes and accelerating the transformation of technological innovation into industrial value.

Focusing on Verticals, Landing Multiple Partnerships with Industry Leaders, Spanning Multi-Scenario Applications in Synthetic Biology

In July 2024, Bota Bio and fine chemicals leader NHU, building on their strategic partnership, announced that their first collaborative project had successfully reached commercialization. This collaboration demonstrated Bota Bio's ability to move technology from the lab to large-scale industrial production.

The successful partnership with NHU strongly validates Bota Bio's development strategy: using core technological capabilities as a starting point to reach cooperation agreements with industry leaders across sectors, building a synthetic biology industry chain through global deployment, and accelerating Bota Bio's rapid integration into the industrial end to enable technology-powered industry. The company adheres to this strategy for deep cultivation in each vertical.

In the food sector, Bota Bio upholds a product selection philosophy of "healthier and safer," committed to building a diversified product matrix, continuously driving technological iteration, and leveraging advantages in intelligent manufacturing. It has chosen biopreservation as its entry point into verticals, establishing effective market moats to ensure leading position in this segment. Horizontally, the company has built a complete biopreservation and antimicrobial product line; vertically, it develops compound formulations and clean-label products to stay close to customer needs, providing scenario-based integrated solutions for clients.

Bota Bio has initiated technology development cooperation with Puratos, a global leader in bread, pastry, and chocolate ingredients. By fully utilizing Puratos's expertise in food and baking science alongside Bota Bio's advanced enzyme discovery and engineering capabilities, the partnership expands Puratos's natural enzyme product line to meet growing market demand for natural ingredients.

In the skincare sector, Bota Bio established its wholly-owned subsidiary Yucca Elements. Multiple bio-identical protein-based personal care ingredient products have been launched, including innovative ingredients that enhance the skin's natural healing abilities, as well as premium anti-aging ingredients that activate gene expression at the skin's foundation. These products have already been incorporated into products from leading domestic skincare companies and have received widespread acclaim.

2024 marks Bota Bio's fifth year since founding and another milestone as the company embarks on a new journey. Going forward, Bota Bio will remain true to its original mission, continuing to drive the transformation from digitalization to intelligence, improving product R&D efficiency, and providing better biomanufacturing solutions starting from industry needs and pain points. The company looks forward to working with experts, scholars, industry partners, and investor friends to jointly drive continuous evolution and breakthroughs in synthetic biology.